Early Response to Everolimus Therapy Detected on Ga-68-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor

Abstract

Everolimus is a mammalian target of rapamycin inhibitor that has been recently approved for the treatment of patients with advanced progressive pancreatic neuroendocrine tumor. Here, we present a case in which an early therapy response to everolimus was effectively demonstrated by Ga-68-DOTATATE PET/CT.